MYMD VS NRBO Stock Comparison

Performance

MYMD
10/100

MYMD returned -82.67% in the last 12 months. Based on SPY's performance of -12.16%, its performance is below average giving it a score of 10 of 100.

NRBO
10/100

NRBO returned -68.60% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

MYMD
25/100

MYMD receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

NRBO
10/100

NRBO receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Profit

MYMD
10/100

Out of the last 20 quarters, MYMD has had 0 profitable quarters and has increased their profits year over year on 1 of them.

NRBO
10/100

Out of the last 20 quarters, NRBO has had 0 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

MYMD
40/100

MYMD has had a lower than average amount of volatility over the last 12 months giving it a score of 39 of 100.

NRBO
57/100

NRBO has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

Earnings

MYMD

"Earnings" not found for MYMD

NRBO
26/100

NRBO has missed earnings 4 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

MyMD Pharmaceuticals, Inc. Common Stock (DE) Summary

Nasdaq / MYMD

Healthcare

Biotechnology

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

NeuroBo Pharmaceuticals, Inc. Common Stock Summary

Nasdaq / NRBO

Healthcare

Biotechnology

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Power up your portfolio